FGFR3 and achondroplasia: Recently, we have also developed a postnatal soluble FGFR3 (sFGFR3) therapy that counteracted the negative effect of FGFR3 signaling by restoring bone growth in an animal model of achondroplasia.(21) Recifercept is an optimized version of sFGFR3 that is currently evaluated in phase 2 clinical trial.